A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease
<p>Abstract</p> <p>Background</p> <p>Hyperphosphatemia in patients with chronic kidney disease (CKD) contributes to secondary hyperparathyroidism, soft tissue calcification, and increased mortality risk. This trial was conducted to examine the efficacy and safety of cal...
Main Authors: | Ho Chiang-Hong, Kessler Paul, Moustafa Moustafa, Solomon Richard, Winkelmayer Wolfgang C, Qunibi Wajeh, Greenberg Jonathan, Diaz-Buxo Jose A |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-02-01
|
Series: | BMC Nephrology |
Online Access: | http://www.biomedcentral.com/1471-2369/12/9 |
Similar Items
-
The excretion of calcium and phosphorus by the human kidney
by: Dowdle, Eugene Bernard Davey
Published: (2020) -
Delayed Manifestation of Shunt Nephritis: A Case Report and Review of the Literature
by: Michael Babigumira, et al.
Published: (2017-01-01) -
Efficacy and safety of calcium acetate-magnesium carbonate in the treatment of hyperphosphatemia in dialysis patients
by: Imed Helal, et al.
Published: (2016-01-01) -
Calcium and Phosphorus Metabolism in Chronic Kidney Disease
by: D.D. Ivanov
Published: (2012-02-01) -
Effects of probiotic supplementation on inflammatory biomarkers and uremic toxins in non-dialysis chronic kidney patients: A double-blind, randomized, placebo-controlled trial
by: Amanda de Faria Barros, et al.
Published: (2018-07-01)